News Abbott Laboratories Deutsche Boerse AG

Stocks

ABL0

CA0028221046

Medical Equipment, Supplies & Distribution

Delayed Deutsche Boerse AG 02:25:23 2026-09-04 EDT			5-day change	1st Jan Change
11.80 ^EUR	-1.67%		-1.67%	-11.94%

09-01	Mead Johnson wins US federal bellwether trial over preterm infant formula Enfamil	RE
09-01	Medtronic Raises Full-Year Outlook Following Fiscal First-Quarter Beat	MT

All News

Mentions Relevance

08-31	Colorectal Cancer Alliance and Abbott Launch Online Hub Explaining Unexpected Home Delivery Of Colorectal Cancer Screening Kits	CI
08-31	Abbott Launches Similac 360 Total Care Made with Whole Milk Ready-To-Feed Liquid Infant Formula in the United States	CI
08-31	Abbott Laboratories : Late-breaking data for Abbott’s TactiFlex™ Duo Ablation Catheter reveal positive outcomes for treating complex AFib cases	PU
08-31	Abbott Laboratories Introduces Similac 360 Total Care Made With Whole Milk in US	MT
08-31	Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula	PR
08-30	Abbott Presents Positive 12-Month Outcomes for Tactiflex Duo Ablation Catheter in Treating Complex Afib Cases	CI
08-27	Abbott Laboratories Insider Sold Shares Worth $46,204,798, According to a Recent SEC Filing	MT
08-27	Abbott Laboratories' Stroke Treatment Device Receives CE Mark	MT
08-27	Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke	PR
08-26	FDA clears Abbott's first sensor to continuously measure glucose and ketones
08-25	Abbott Receives Fda Authorization for Libre Duo 10 Day Dual Glucose-Ketone Sensing Technology	CI
08-25	Abbott Laboratories Gets Regulatory Authorization for Dual Glucose-Ketone Sensor	MT
08-25	FDA authorizes Abbott's wearable to monitor ketone and glucose in diabetes patients	RE
08-25	Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes	PR
08-21	TD Cowen Adjusts Price Target on Abbott Laboratories to $135 From $115, Maintains Buy Rating	MT
08-20	Abbott to pay $670 million to settle some preterm infant formula cases	RE
08-20	Abbott Reaches $670 Million Settlement Over Infant Formula Claims	MT
08-20	Abbott to Pay $670 Million to Settle Baby-Formula Litigation	DJ
08-20	Abbott reaches agreements to resolve portion of litigation over infant formula	RE
08-20	Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants	PR
08-20	Abbott Laboratories Signs Supply, Distribution Deal With Avricore Health's HealthTab Unit	MT
08-20	Healthtab Ltd and Abbott Enter Multi-Year Collaboration Agreement for Point-Of-Care Testing Across the Uk	CI
08-17	Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare	PR
08-13	Citigroup Adjusts Price Target on Abbott Laboratories to $125 From $112, Maintains Buy Rating	MT
08-13	Wolfe Research Upgrades Abbott Laboratories to Outperform From Peer Perform, PT is $130	MT